Rep. Steve Scalise is diagnosed with blood cancer and undergoing treatment
The No. 2-ranking House Republican described the cancer as ‘very treatable’ and said it was detected early

Rep. Steve Scalise, the No. 2-ranking House Republican, said Tuesday he has been diagnosed with a form of blood cancer known as multiple myeloma and is undergoing treatment. Scalise, 57, said he will continue to serve in the House. He described the cancer as “very treatable” and said it was detected early.
The Louisiana Republican was among several people wounded in 2017 when a rifle-wielding attacker fired on lawmakers on a baseball field in Alexandria, Virginia, outside Washington. Scalise was shot in the hip and endured lengthy hospitalizations, multiple surgeries and painful rehabilitation.
The cancer diagnosis came, Scalise said, after he had not been feeling like himself in the past week. Blood tests showed some irregularities and after additional screening, he said he was diagnosed with multiple myeloma.
“I have now begun treatment, which will continue for the next several months,” Scalise said in a statement. “I expect to work through this period and intend to return to Washington, continuing my work as Majority Leader and serving the people of Louisiana’s First Congressional District.”
Scalise also thanked his medical team and said he was “incredibly grateful we were able to detect this early and that this cancer is treatable.”
“I will tackle this with the same strength and energy as I have tackled past challenges,” Scalise said.
Colleagues in the House and members of Louisiana’s congressional delegation offered Scalise and his family their encouragement in response to the announcement, some recalling his determination following the 2017 shooting.
“The same faith, family support, and internal strength that made Steve such an inspiration to others after he was shot will bring him through this illness and once more inspire us all,” said Sen. Bill Cassidy, R-La.
Sign up for our weekly newsletter to get more English-language news coverage from EL PAÍS USA Edition
Tu suscripción se está usando en otro dispositivo
¿Quieres añadir otro usuario a tu suscripción?
Si continúas leyendo en este dispositivo, no se podrá leer en el otro.
FlechaTu suscripción se está usando en otro dispositivo y solo puedes acceder a EL PAÍS desde un dispositivo a la vez.
Si quieres compartir tu cuenta, cambia tu suscripción a la modalidad Premium, así podrás añadir otro usuario. Cada uno accederá con su propia cuenta de email, lo que os permitirá personalizar vuestra experiencia en EL PAÍS.
¿Tienes una suscripción de empresa? Accede aquí para contratar más cuentas.
En el caso de no saber quién está usando tu cuenta, te recomendamos cambiar tu contraseña aquí.
Si decides continuar compartiendo tu cuenta, este mensaje se mostrará en tu dispositivo y en el de la otra persona que está usando tu cuenta de forma indefinida, afectando a tu experiencia de lectura. Puedes consultar aquí los términos y condiciones de la suscripción digital.
More information
Archived In
Últimas noticias
More than 40 Democratic lawmakers urge Trump in a letter to stop his ‘attempts to undermine democracy in Brazil’
The journal ‘Science’ criticizes Trump’s anti-renewable energy policy: ‘The US is failing to benefit from its own innovations’
Cubans hope for a miracle as dengue and chikungunya spread
The long shadow of the father figure in the films of Rob Reiner
Most viewed
- Christian Louboutin: ‘Young people don’t want to be like their parents. And if their parents wear sneakers, they’re going to look for something else’
- Cartels in Mexico take a leap forward with narco-drones: ‘It is criminal groups that are leading the innovation race’
- ‘El Limones’ and the growing union disguise of Mexican organized crime
- Liset Menéndez de la Prida, neuroscientist: ‘It’s not normal to constantly seek pleasure; it’s important to be bored, to be calm’
- The low-cost creative revolution: How technology is making art accessible to everyone









































